For the millions of adults living with depression, the standard path is familiar: try an antidepressant, wait several weeks to see if it works, and if it doesn’t, try another. For some people, relief eventually comes. But for roughly one in three adults with major depressive disorder, that cycle repeats again and again without the breakthrough they’re hoping for.
This is what clinicians call treatment-resistant depression (TRD)—depression that hasn’t responded adequately to at least two different antidepressant medications.
If that describes you or someone you love, Spravato (esketamine) may offer something the traditional approach hasn’t: a genuinely different mechanism, and often, faster relief. Here’s what makes it worth understanding.
1. It Works on the Brain in a Fundamentally Different Way
Most antidepressants—SSRIs, SNRIs, and their relatives—act on serotonin and norepinephrine. They can be effective, but they target the same general pathways, which is part of why switching from one to another sometimes yields the same disappointing result.
Spravato takes a different route entirely. Esketamine targets the brain’s glutamate system, glutamate being the most abundant excitatory neurotransmitter in the brain.
Promotes synaptic connections: Researchers believe this helps support the brain’s ability to form new neural pathways—a process tied to mood regulation.
A fresh approach: For someone who has cycled through serotonin-based medications without success, that different mechanism is precisely the point. It’s not another version of what didn’t work; it’s a new approach.
2. Relief Can Come in Days, Not Weeks
One of the hardest parts of conventional antidepressant treatment is the wait. It typically takes four to six weeks to know whether a medication is helping—a long stretch for anyone, and an especially difficult one for people in significant distress.
Spravato can work much faster. In clinical studies, patients experienced improvement in depressive symptoms in as little as 24 hours, with continued benefit measured through the first month of treatment. For people who have spent months or years waiting for relief that never fully arrived, the possibility of feeling meaningfully better within days rather than weeks can be life-changing.
3. It’s Now Approved as a Standalone Treatment
In January 2025, the FDA approved Spravato as the first and only monotherapy for adults with treatment-resistant depression. This was a meaningful shift. Previously, Spravato had to be paired with a daily oral antidepressant. Now it can be prescribed on its own.
Why does monotherapy matter?
Avoid side effects: For many patients, daily oral antidepressants come with side effects they’d rather avoid—sexual dysfunction, weight changes, or digestive issues, among others.
Reduce pill burden: Others are already managing a heavy pill burden and don’t want to add yet another daily medication.
Personalized care: The monotherapy option lets clinicians personalize treatment more precisely, giving patients the benefits of Spravato without the complexity of an additional daily prescription.
4. Treatment Happens in a Supportive, Supervised Setting
Spravato isn’t a prescription you fill at the pharmacy and take at home. It’s administered as a nasal spray in a certified healthcare setting under medical supervision, and that structure is a feature, not an inconvenience.
What to Expect During a Session: Each session takes place in a calm, monitored environment. After self-administering the spray under staff guidance, patients are observed for about two hours to ensure they’re comfortable and safe before heading home (with someone else driving).
For people who have felt isolated in their struggle with depression, this regular, supported contact with a care team can itself become part of the healing—a recurring point of connection rather than a solitary daily routine.
5. A Targeted Option for Rapid Support
Beyond treatment-resistant depression, esketamine is also recognized for its role in helping adults with major depressive disorder who are experiencing acute suicidal thoughts or behavior, where rapid symptom improvement can be especially urgent. This reflects a broader truth about Spravato: it was developed for the people who need a different answer most.
Is Spravato Right for You?
Spravato is a powerful option, but it isn’t the right fit for everyone, and a thoughtful evaluation matters. Because it’s a controlled medication administered under supervision, it’s offered through a careful, structured program that prioritizes patient safety.
Common effects during and shortly after treatment can include:
A sense of dissociation
Dizziness
Temporary sedation
(This is exactly why the in-office monitoring period exists.) A qualified provider will review your history, your previous treatments, and your goals to determine whether Spravato is an appropriate next step.
Remember: If traditional antidepressants haven’t given you the relief you’ve been searching for, your options are not exhausted. Treatment-resistant depression is treatable, and Spravato represents one of the most significant advances in depression care in decades.
Take the Next Step with EverHope
At EverHope Wellness Center, we specialize in Spravato treatment for adults with treatment-resistant depression. Our team provides the certified setting, clinical expertise, and compassionate, individualized care that this therapy calls for—guiding you through every session in a comfortable, supportive environment.
If you’ve been waiting for something different, we’d welcome the chance to talk with you about whether Spravato could be part of your path forward.
